APA

Hepburn A. C., Steele R. E., Veeratterapillay R., Wilson L., Kounatidou E. E., Barnard A., Berry P., Cassidy J. R., Moad M., El-Sherif A., Gaughan L., Mills I. G., Robson C. N. & Heer R. (20191011). The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance. : Oncogene.

Chicago

Hepburn A C, Steele R E, Veeratterapillay R, Wilson L, Kounatidou E E, Barnard A, Berry P, Cassidy J R, Moad M, El-Sherif A, Gaughan L, Mills I G, Robson C N and Heer R. 20191011. The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance. : Oncogene.

Harvard

Hepburn A. C., Steele R. E., Veeratterapillay R., Wilson L., Kounatidou E. E., Barnard A., Berry P., Cassidy J. R., Moad M., El-Sherif A., Gaughan L., Mills I. G., Robson C. N. and Heer R. (20191011). The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance. : Oncogene.

MLA

Hepburn A C, Steele R E, Veeratterapillay R, Wilson L, Kounatidou E E, Barnard A, Berry P, Cassidy J R, Moad M, El-Sherif A, Gaughan L, Mills I G, Robson C N and Heer R. The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance. : Oncogene. 20191011.